| The MD Anderson prostate cancer patient-derived xenograft series (MDA PCa PDX) captures the molecular landscape of prostate cancer and facilitates marker-driven therapy development N Palanisamy, J Yang, PDA Shepherd, EM Li-Ning-Tapia, E Labanca, ... Clinical Cancer Research 26 (18), 4933-4946, 2020 | 64 | 2020 |
| Heme oxygenase-1 in the forefront of a multi-molecular network that governs cell–cell contacts and filopodia-induced zippering in prostate cancer AV Paez, C Pallavicini, F Schuster, MP Valacco, J Giudice, EG Ortiz, ... Cell death & disease 7 (12), e2570-e2570, 2016 | 42 | 2016 |
| Game-changing restraint of Ros-damaged phenylalanine, upon tumor metastasis G Gueron, N Anselmino, P Chiarella, EG Ortiz, S Lage Vickers, AV Paez, ... Cell Death & Disease 9 (2), 140, 2018 | 23 | 2018 |
| Fibroblast growth factors signaling in bone metastasis E Labanca, ES Vazquez, PG Corn, JM Roberts, F Wang, CJ Logothetis, ... Endocrine-related cancer 27 (7), R255-R265, 2020 | 21 | 2020 |
| Heme oxygenase-1 is a pivotal modulator of bone turnover and remodeling: molecular implications for prostate cancer bone metastasis N Anselmino, M Starbuck, E Labanca, J Cotignola, N Navone, G Gueron, ... Antioxidants & redox signaling 32 (17), 1243-1258, 2020 | 17 | 2020 |
| HO-1 interactors involved in the colonization of the bone niche: role of ANXA2 in prostate cancer progression N Anselmino, J Bizzotto, P Sanchis, S Lage-Vickers, E Ortiz, P Valacco, ... Biomolecules 10 (3), 467, 2020 | 17 | 2020 |
| Association of HO-1 and BRCA1 is critical for the maintenance of cellular homeostasis in prostate cancer E Labanca, P De Luca, G Gueron, A Paez, CP Moiola, C Massillo, ... Molecular Cancer Research 13 (11), 1455-1464, 2015 | 17 | 2015 |
| The expression of YWHAZ and NDRG1 predicts aggressive outcome in human prostate cancer S Lage-Vickers, J Bizzotto, MP Valacco, P Sanchis, S Nemirovsky, ... Communications Biology 4 (1), 103, 2021 | 16 | 2021 |
| Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel E Labanca, J Bizzotto, P Sanchis, N Anselmino, J Yang, PDA Shepherd, ... Oncogene 40 (44), 6284-6298, 2021 | 15 | 2021 |
| Fibroblast growth factor receptor 1 drives the metastatic progression of prostate cancer E Labanca, J Yang, PDA Shepherd, X Wan, MW Starbuck, LD Guerra, ... European Urology Oncology 5 (2), 164-175, 2022 | 12 | 2022 |
| HO-1 modulates aerobic glycolysis through LDH in prostate cancer cells F Cascardo, N Anselmino, A Páez, E Labanca, P Sanchis, ... Antioxidants 10 (6), 966, 2021 | 10 | 2021 |
| Pin-pointing the key hubs in the IFN-γ pathway responding to SARS-CoV-2 infection A Toro, S Lage-Vickers, J Bizzotto, F Vilicich, A Sabater, G Pascual, ... Viruses 14 (10), 2180, 2022 | 6 | 2022 |
| Myxovirus resistance protein 1 (MX1), a novel HO-1 interactor, tilts the balance of endoplasmic reticulum stress towards pro-death events in prostate Cancer E Ortiz, P Sanchis, J Bizzotto, S Lage-Vickers, E Labanca, N Navone, ... Biomolecules 10 (7), 1005, 2020 | 6 | 2020 |
| Bone progenitors pull the strings on the early metabolic rewiring occurring in prostate cancer cells P Sanchis, N Anselmino, S Lage-Vickers, A Sabater, R Lavignolle, ... Cancers 14 (9), 2083, 2022 | 5 | 2022 |
| Modeling cancer metastasis NM Navone, E Labanca Patient-Derived Xenograft Models of Human Cancer, 93-114, 2017 | 4 | 2017 |
| Exploiting interdata relationships in prostate cancer proteomes: clinical significance of HO-1 interactors S Lage-Vickers, P Sanchis, J Bizzotto, A Toro, A Sabater, R Lavignolle, ... Antioxidants 11 (2), 290, 2022 | 3 | 2022 |
| Coronavirus pathogenesis in mice explains the SARS-CoV-2 multi-organ spread by red blood cells hitch-hiking A Toro, AP Arevalo, M Pereira-Gómez, A Sabater, EA Zizzi, G Pascual, ... medRxiv, 2023.03. 29.23287591, 2023 | 2 | 2023 |
| Integrative analysis of the MD anderson prostate cancer patient-derived xenograft series (MDA PCa PDX) N Anselmino, E Labanca, X Song, J Yang, PDA Shepherd, J Dong, ... bioRxiv, 2022.07. 21.500652, 2022 | 2 | 2022 |
| A specific pan-FGFR inhibitor has antitumor activity against prostate cancer patient derived xenografts, PDX, expressing high FGFR1 E Labanca, J Yang, P Shepherd, X Wan, JM Roberts, MW Starbuck, ... Cancer research 78 (13_Supplement), 2870-2870, 2018 | 1 | 2018 |
| Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer M Archer, D Begemann, E Gonzalez-Kozlova, PR Nepali, E Labanca, ... Molecular Cancer Research, 2024 | | 2024 |
